Atlas Venture Life Science Advisors, LLC

2. Key Holdings

The portfolio is characterized by extreme concentration, with the top two positions comprising over 95% of the total assets under management (AUM).

• Dyne Therapeutics, Inc. (DYN) is the dominant holding, valued at $115.50 million and representing 68.35% of the portfolio. With a position size of 9.13 million shares, this is clearly the manager's primary conviction bet.
• Day One Biopharmaceuticals, Inc. (DAWN) is the second-largest position, accounting for 26.83% of the portfolio at $45.33 million. Together, DYN and DAWN form the core of the firm's equity exposure.
• The remaining positions, Generation Bio, Co. (3.00%) and ImageneBio, Inc. (1.82%), are marginal in comparison. The small weighting of Generation Bio is particularly notable given that it was a significant focus in the previous quarter before a massive reduction in shares.